| CAS登錄號 | 中文名 | 英文名 | 分子結構式 | 分子式 | 詳情 | 供應商 |
| 144494-65-5 | 替羅非班; (2S)-2-(丁基磺酰氨基)-3-[4-[4-(4-哌啶基)丁氧基]苯基]丙酸 | Tirofiban; (2S)-2-(Butylsulfonylamino)-3-[4-[4-(4-piperidyl)butoxy]phenyl]propanoic acid |  | C22H36N2O5S | 詳情 | 供應商 |
| 124709-28-0 | Benzoic acid,2,4-dihydroxy-6-[(14R)-14-hydroxypentadecyl]-; Benzoicacid, 2,4-dihydroxy-6-(14-hydroxypentadecyl)-, (R)-; (-)-Phanerosporic acid; MC304; Phanerosporic acid |  | C22H36O5 | 詳情 | 供應商 | |
| 151065-53-1 | L-Tyrosine,N-(butylsulfonyl)-O-[4-(4-piperidinyl)butyl]-; Aggrestat; N-(Butylsulfonyl)-O-[4-(4-piperidinyl)butyl]-L-tyrosine; Tirofiban |  | C22H36N2O5S | 詳情 | 供應商 | |
| 34099-72-4 | Hexadecanoic acid,(5-hydroxy-4-oxo-4H-pyran-2-yl)methyl ester; Palmiticacid, 2-ester with 5-hydroxy-2-(hydroxymethyl)-4H-pyran-4-one (7CI,8CI); Kojilpalmitate; NSC 10217 |  | C22H36O5 | 詳情 | 供應商 | |
| 64318-77-0 | Prosta-2,13-dien-1-oicacid, 11,15-dihydroxy-16,16-dimethyl-9-oxo-, (2E,11a,13E,15R)- (9CI); trans-2,3-Didehydro-16,16-dimethyl-PGE1 |  | C22H36O5 | 詳情 | 供應商 | |
| 54120-61-5 | Prosta-4,5,13-trien-1-oicacid, 9,11,15-trihydroxy-15-methyl-, methyl ester, (9a,11a,13E,15R)-(?à)-; Prostalene; RS 9390; Synchrocept |  | C22H36O5 | 詳情 | 供應商 | |
| 39746-25-3 | Prosta-5,13-dien-1-oicacid, 11,15-dihydroxy-16,16-dimethyl-9-oxo-, (5Z,11a,13E,15R)-; 16,16-Dimethyl-PGE2; 16,16-Dimethylprostaglandin E2 |  | C22H36O5 | 詳情 | 供應商 | |
| 98677-35-1 | Prost-13-en-1-oic acid,15-hydroxy-10,10-dimethyl-6,9-dioxo-, (13E,15S)- (9CI); NP 01A |  | C22H36O5 | 詳情 | 供應商 | |
| 64072-59-9 | Prosta-5,13-dien-1-oicacid, 9,15-dihydroxy-16,16-dimethyl-11-oxo-, (5Z,9a,13E,15S)- (9CI); 16,16-Dimethyl-PGD2 |  | C22H36O5 | 詳情 | 供應商 | |
| 81026-63-3 | Prosta-4,13-dien-1-oicacid, 11,16-dihydroxy-16-methyl-9-oxo-, methyl ester, (4Z,11a,13E)-(?à)-; Enisoprost; SC 34301 |  | C22H36O5 | 詳情 | 供應商 | |
| 83162-77-0 | 1-Hexadecanone,14-hydroxy-1-(2,4,6-trihydroxyphenyl)- (9CI); Byssomeruliol D |  | C22H36O5 | 詳情 | 供應商 | |
| 64072-63-5 | 7-Nonenoic acid,9-[(1R,2R,5S)-5-hydroxy-2-[(1E,3S)-3-hydroxy-1-octen-1-yl]-3-oxocyclopentyl]-,(7Z)-; 7-Nonenoicacid, 9-[5-hydroxy-2-(3-hydroxy-1-octenyl)-3-oxocyclopentyl]-, [1R-[1a(Z),2b(1E,3S*),5a]]-; 1a,1b-Dihomoprostaglandin D2; 2a,2b-Dihomo-PGD2 |  | C22H36O5 | 詳情 | 供應商 | |
| 26198-80-1 | 7-Nonenoic acid,9-[(1R,2R,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxy-1-octen-1-yl]-5-oxocyclopentyl]-,(7Z)-; 7-Nonenoicacid, 9-[(1R,2R,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxy-1-octenyl]-5-oxocyclopentyl]-,(7Z)- (9CI); 7-Nonenoic acid,9-[3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl]-, [1R-[1a(Z),2b(1E,3S*),3a]]-; 7-Nonenoic acid,9-[3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl]-, stereoisomer (8CI); 1a,1b-Dihomoprostaglandin E2; a-Dihomoprostaglandin E2 |  | C22H36O5 | 詳情 | 供應商 | |
| 74397-12-9 | 17S-Methyl-w-homo-trans-D2-PGE1 |  | C22H36O5 | 詳情 | 供應商 | |